Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.39 |
| ▸ | DRD3 | P35462 | 6/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 4/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | DRD5 | P21918 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7597866 | 0.90 | SLC22A12 (0.33) | DRD2DRD3HTR1DSLC22A12MRGPRX4 | |
| SCHEMBL6207099 | 0.84 | PPARG (0.43) | DRD2DRD3HTR1DDRD4SLC22A12 | |
| SCHEMBL15453472 | 0.83 | HSD11B1 (0.36) | SLC22A12MRGPRX4 | |
| Iodide SCHEMBL7773907 | 0.82 | PPARG (0.42) | DRD2DRD3HTR1DDRD4SLC22A12 | |
| SCHEMBL19948194 | 0.81 | DRD2 (0.41) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL3082218 | 0.81 | MRGPRX4 (0.46) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL15765781 | 0.81 | CNR2 (0.38) | SLC22A12MRGPRX4RXRARXRBRXRG | |
| SCHEMBL18374895 | 0.81 | DRD2 (0.35) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL19948204 | 0.80 | FABP1 (0.38) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL29428702 | 0.80 | FABP1 (0.38) | DRD2DRD3HTR1DDRD4HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | BRPF1, PFAS, FLI1 | DRD2 2483/4885DRD3 2723/4885HTR1D 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.